IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验,用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors

动脉网
Yesterday

by GOAI由GOAI生成Share To分享到IDEAYA Biosciences has initiated its Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate (ADC) targeting B7H3 and PTK7. The company announced that the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10